
3rd International Electronic Conference on Medicinal Chemistry
Part of the International Electronic Conference on Medicinal Chemistry series
1–30 Nov 2017
- Go to the Sessions
- Event Details
Welcome from the Chair
Further to the success of the two first editions, Pharmaceuticals, a peer-reviewed journal edited by MDPI, is proud to organize and sponsor the 3rd International Electronic Conference on Medicinal Chemistry. Contributions dealing with any discipline promoting research in drug discovery and development will be welcome.
The conference will be held online (www.sciforum.net/conference/ecmc-3) from November 1–30, 2017. It will enable you to share your recent results with scientists of academic and industrial groups from all over the world.
Participation, as an author or a visitor, is ABSOLUTELY FREE (simply create an account on the home page). Abstracts of the presentations will be published, upon authorization of the authors, in a meeting report after the conference.
On behalf of our dynamic editorial staff and active scientific committee, we warmly invite you to join us during this third edition and we look forward to posting your contributions.
All participants of ECMC-3 are welcome to submit the extended work to the Pharmaceuticals Special Issue "Selected Papers from the 3rd International Electronic Conference on Medicinal Chemistry".
Conference Chair
Dr. Jean Jacques Vanden Eynde |
![]() |
Conference Committee
IPBLN-CSIC, Spain |
Universidade do Porto, Portugal |
University of Nebraska Medical Center, USA |
Haute Ecole Provinciale de Hainaut-Condorcet, Belgium |
Université Libre de Bruxelles, Belgium |
Universidade Federal do Rio de Janeiro, Brazil |
Università degli Studi di Cagliari, Italy |
Call for Papers
The conference will cover a wide range of aspects involved in drug discovery and development. A non exhaustive list of topics that will be considered comprises:
- ADMET
- Animal experimentation
- Assay development
- Biomarkers
- Biomolecules
- Biosensors
- Biotechnology
- Chemical synthesis
- Clinical studies and side effects reports
- Combinatorial chemistry
- Drug delivery (including bioconjugates and prodrugs)
- High throughput screening
- Hit identification
- Imaging techniques
- In silico experiments
- In vitro studies
- Lead optimization
- Omics
- Pharmaceutical analysis
- Scale-up
- Structure–activity relationships
- Target selection
After the conference, proceedings will be published free of charge thanks to the sponsoring of the journal Pharmaceuticals, in a meeting report. Authors of the most outstanding contributions, as selected by the Scientific Committee, will be invited to publish their work as a research article free of charge or at a discounted price, in a Special Issue of the journal Pharmaceuticals.
The Scientific Committee looks forward to receiving contributions in response to this call and will be glad to provide any further information to interested parties. Questions may be addressed to the chairman via e-mail at [email protected] or to the Pharmaceuticals editorial office at [email protected].
We thank you in advance for your attendance of this conference and look forward to a stimulating exchange.
Conference Chairs

Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium
[email protected]
Conference Committee

Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra, (IPBLN-CSIC), PTS Granada, Av del Conocimiento 17, 18016 Granada, Spain
structure-function of RNA; aptamers; antisense; ribozymes; viral RNA genomes; RNA as tool; therapeutic RNAs
[email protected]

Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências, Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira 228, 4050-313, Porto, Portugal
medicinal chemistry; organic synthesis; heterocycles, P-glycoprotein; anticancer; anticoagulants; chiral drugs; marine natural products
[email protected]

Department of Pathology & Microbiology University of Nebraska Medical Center, USA
host defense antimicrobial peptides, structural bioinformatics, biomolecular NMR
[email protected]

Formerly professor at the Haute Ecole Provinciale de Hainaut-Condorcet, 7330 Saint-Ghislain, Belgium
medicinal chemistry, organic synthesis, parasitic diseases, orphan drugs
[email protected]

Faculté de Pharmacie, Université Libre de Bruxelles, Campus Plaine CP 205/5, 1050 Brussels, Belgium
medicinal chemistry; anticancer metal complexes; asymmetric synthesis
[email protected]

Universidade Federal do Rio de Janeiro, IPPN, CCS, Bloco H - Ilha do Fundão, Rio de Janeiro, RJ - 21941-902, Brazil
molecular modeling; computer-aided drug design; bioinformatics; chemoinformatics
[email protected]

Università degli Studi di Cagliari, Dipartimento di Scienze Chimiche e Geologiche, Cittadella Universitaria, SS 554, bivio per Sestu, 09042, Monserrato (CA), Italy
peptide synthesis; peptide nucleic acid; indole synthesis; amide synthesis; mechanochemical reaction; borrowing hydrogen; microwave; heterocycle synthesis; hydroxamic acids
[email protected]
Instructions for Authors
Submissions should be done by the authors online by registering with www.sciforum.net, and using the "Start New Submission" function once logged into system.
Researchers interested in attending the conference must submit, on this website and not later than 15 October 2017, an abstract of the work they intend to present.
After the abstract is accepted by the Scientific Committee (1-5 days after receipt of the abstract), the authors will be invited to prepare a full description of their work preferably under the form of a PowerPoint presentation, and to upload it before 20 October 2017 to ensure final check.
The presentations will be accessible on https://sciforum.net/conference/ecmc-3 during the time of the conference.
Authors are encouraged to prepare a presentation using the template provided by the conference. Slides will be displayed directly in the website using Sciforum.net's proprietary slides viewer. They can be prepared in exactly the same way as for any traditional conference where research results can be presented. Slides should be converted to the PDF format before submission so that our process can easily and automatically convert them for online displaying.
Electronic Conference on Medicinal Chemistry PPT template file
Electronic Conference on Medicinal Chemistry Poster template file
The following organization is recommended for your presentation:
- Length of the presentation: no more than 30 slides
- Slide 1 (strictly one slide): Title, Authors’ names, Affiliation(s), email address of the corresponding Author, and, not mandatory, logos of the laboratory and/or institution;
- Slide 2 (strictly one slide): Graphical Abstract, repeat the title of the presentation but avoid other text as far as possible;
- Slide 3 (strictly one slide): Abstract (max 200 words) and 3-5 keywords separated by semicolons;
- Slide 4 and following slides: should contain (in the given sequence) Introduction, Results and Discussion; Conclusions.
- Last slide: Acknowledgments and, not mandatory, logos of sponsors of the work.
MDPI AG, the publisher of the Sciforum.net platform, is an open access publisher. We believe that authors should retain the copyright to their research works. Hence, by submitting a contribution to this conference, the authors retain the copyright of their contribution, but they grant MDPI AG the non-exclusive right to publish this contribution online on the Sciforum.net platform. This means the authors can easily submit their contribution to any scientific journal at a later stage and transfer the copyright to its publisher (if required by that publisher).
List of accepted submissions (76)
Id | Title | Authors | Presentation | ||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
sciforum-014287 | Drug Targeting of Natural Products: the Example of Antileishmanial Quinolines | , , , , , , , , |
![]() |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
Leishmaniases are a complex of tropical and sub-tropical diseases caused by parasites of the genus Leishmania and transmitted by the bite of an insect vector, the sandfly. Quinolines of natural origin have shown interesting antileishmanial activities on several experimental leishmaniasis models. A classical daily treament with 2-n-propylquinoline (2-n-PQ) on five consecutive days in mice model is not sufficient to cure the mice infected with Leishmania donovani and the activity requires a 10-day treatment duration whatever the route (oral, parenteral) because of a short half-life elimination of the drug. Therefore, 2-n-PQ derivatives were bound to soluble polysaccharides to improve their solubility, delay their elimination half-life and therefore enhance the activity. In vitro release at 37ºC in phosphate buffer was performed in various conditions and showed that around 65% of the compound was released in 24 h. In vitro, the most active conjugate was the dextran-2PQA conjugate exhibiting an IC50 value at 12 µg/mL on Leishmania donovani intramacrophage amastigotes. However, this system did not allow a sufficient release of the active principle explaining the lack of in vivo activity. Another approach consisted in administering 2-n-PQ intravenously. Two systems were successful both in vitro and in vivo : a liposomal formulation named 2-n-PQ-LIP and a hydroxypropyl beta-cyclodextrin inclusion complex designated as 2-n-PQ-HPC. The most interesting one was the liposomal formulation, active on the L. donovani Balb/c mouse model, by reducing the parasite burden by more than 80% after an intravenous treatment regimen of 3 mg equivalent 2-n-PQ/kg/day given on five consecutive days. No synergistic activity between 2-n-PQ and Amphotericin B was monitored either in vitro or in vivo. These formulations should be studied further on other leishmaniasis models and for toxicological considerations. Acknowledgements This work was supported by a grant from the Indo-French Centre of Advanced Research, New Delhi (CEFIPRA) (No. 4803-04) and Kaluvu Balaraman was recipient of a CEFIPRA postdoctoral fellowship. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-014263 | Activity of Vitamin E Phosphate (VEP) Prodrugs of Gemcitabine in a Xenograft Model of NSCLC (NCI-H460) |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||||
VEP nucleosides bypass two mechanisms of tumor resistance: nucleoside transport and kinase downregulation. Isoforms of VE have shown activity against solid and hematologic tumors. Gemcitabine was conjugated at the 5’ position to either δ-tocopherol-MP (NUC050) or δ-tocotrienol-MP (NUC052). NUC050 has been demonstrated to deliver gemcitabine-MP intracellularly. Its half-life IV in mice is 3.9 compared to 0.28 hours for gemcitabine (European J Cancer. 2016. 61(Suppl. 1):S119). When tumors in nude mice reached 32 to 75 mg mm3 (day 4) treatment was initiated with gemcitabine (120 mg/kg IP q3dx9), NUC050 or NUC052 (both 40 mg/kg qwkx4) and compared to saline control (SC). Gemcitabine inhibited tumor growth but was not tolerated. NUC050 resulted in inhibition to tumor growth on days 11-31 (p<0.05), with a nadir of -73% compared to SC. Median survival was 25.5 days (SC) vs 33 days (NUC050) ((hazard ratio) HR=0.24, p=0.017). NUC052 had the dose increased to 50 mg/kg after 2 doses. NUC052 resulted in inhibition to tumor growth on days 14-27 (p<0.05), with a nadir of -45%, and median survival was 34 days (HR=0.27, p=0.033). NUC050 and NUC052 have been shown to be safe and effective in a NSCLC xenograft. Studies have been initiated in a pancreatic cancer xenograft. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-014606 | Synthesis of Squaramides with Anti-tumor Activity | , , , , |
![]() |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
In this study, the cytotoxic effects of different squaramides were tested against diverse cancer cells, such as HGC-27, HeLa, T98 and U87 cells, and non-cancer cells, such as EK293, MDCK and Vero cells. The best results were observed in a disubstituted squaramide that showed an IC50 of 1.81 μM against HGC-27 cells, which is a considerably lower value than the IC50 values observed in the rest of the cell lines. Therefore, this squaramide and its derivatives could be promising molecules for the treatment of gastric carcinoma. Furthermore, the mechanism of action of this compound was evaluated. The outcomes indicated that the decrease in cell viability produced by the squaramide is probably caused by G0/G1 cell cycle arrest and caspase-mediated apoptosis. Additionally, the cell death produced by this compound was accompanied by autophagy induction and no signs of cathepsin-mediated cell death and necroptosis were observed. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-014865 | Research on Prospective Pharmacorrection Medications for First-degree Obesity Treatment among Non-natural Substances Containing Chalcogenamido Groups | , |
![]() |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
Alimentary obesity is an important social problem for all developed countries. A variety of factors affects gain of body weight. among which hypodynamia, which is caused by widespread automation. To date, the human diet increases the palm oil content due to its low cost and long shelf life. Detailed research of the effect of excessive amount of palm oil on the body state is very relevant. In the modern world, it is important to search for highly effective and safe medicines for weight loss treatment of metabolic syndrome consequences. This work is dedicated to a search for effective and safe pharmacorrection medications for the first-degree obesity treatment, as the result of excessive consumption of palm oil during a long period of time. Our studies have shown that two new compounds containing chalcogenamide groups have the property of reducing weight. The experiment was performed on 24 white non-linear sexually mature rats of both sexes, which weighed 120-180g. The animals were divided into 4 groups. The animals of the intact group were kept on a standard diet of the vivarium of the State Institution «Lugansk State Medical University», LPR. The second group, the control group, has been receiving palm oil at a dose of 30 g/kg to a daily ration for a period of 6 weeks. The rats of the third and fourth groups have been receiving samples of two new organic compounds 1 and 2).The compounds were administered intragastrically at a dose of 2.5 mg/kg for 2 weeks after a six-week high-fat diet. Once every 7 days the rats were weighed to assess the dynamics of changes in their weight. The body weight of animals had increased by 121% after a six-week high-fat diet. After the first week of pharmacorrection, the third group showed a decrease in weight by 12.17%, and after the second week the animals lost another 10.75%. During the two-week period of administration of the substance 1 the weight of the rats decreased by a factor of 1,27 and approached the values of the body weight of animals of the intact group. There were no animal deaths in this group, the behavioral reactions of rats were adequate. In the latter days of research the flabbiness of the hair-coat was noted. In the fourth experimental group, the mass decreased by 8.02% during the first two-week period. The death of animals was absent, behavioral reactions were adequate. The performed studies have shown that substances 1 {3',9'-dibenzyl-6'-selenoxo-3',4',9',10'- tetrahydro-2'H-spiro[cyclohexane-1,12'-[1,3,5,9] tetraaza[7,11]-methano[1,3,5]triazino[1,2-a] [1,5]diazocine]-7',11'(6'H,8'H)-dicarbonitrile} and 2 {4-(2-chlorophenyl)-2-({[3-methyl-2,6-dioxo-7-(2-oxo- 2-phenylethyl)-2,3,6,7-tetrahydro-1H-purin-8-yl]methyl} thio)-5,6,7,8-tetrahydroquinoline-3-carbonitrile} possessed the properties of prospective pharmacorrection medications for alimentary obesity treatment. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-014453 | Arylideneketones with Potent Trypanosomicidal Activity that Causes Late Apoptosis/Necrosis Like Nifurtimox | , , , , , |
![]() |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
Chagas disease is caused by the parasite Trypanosoma cruzi (T. cruzi). It remains the major parasitic disease in Latin America, despite recent advances in the control of its vector-borne and transfusion mediated transmission. Moreover, migration of infected people has spread the disease to non-endemic areas, presenting a new worldwide challenge. The chemotherapy employed to control the parasitic infection is based on two drugs: Nifurtimox (Nfx) and Benznidazole (Bnz), requiring long-term treatment that can give rise to severe side effects. They are not active against all T. cruzi strains, exhibit low efficiency in long-term chronic infections, and are mutagenic. The search of new drugs is an urgent need. In this work, we used three symmetrical diarylideneketones containing thiophene and furane ((1E,3E,6E,8E)-1,9-Di(furan-2-yl)nona-1,3,6,8-tetraen-5-one (1), (2E,6E)-2,6-Bis((E)-3-(furan-2-yl)allylidene)cyclohexanone (2) and (2E,5E)-2,5-Bis[3-(thiophen-2-yl)allyliden]cyclopentanone (3)). These molecules showed good to excellent trypanosomicidal activity and selectivity to the parasite, affected cruzipain, a proteolytic enzyme of the parasite, and the glycolytic enzyme, triosephosphate isomerase of T. cruzi (TcTIM) without affecting human´s TIM and showing effectiveness in protecting infected mice and without toxic effects in vivo. In addition, these could be obtained by a simple and economic green synthetic route, which is an important feature in the research and development of future drugs for neglected diseases. The type of T. cruzi death caused is an important feature to determine, because it could govern inflammation events unbeneficial in the elimination of the parasite. We studied the mechanism of T. cruzi death using Annexin V and propidium iodide followed by flow cytometry analysis of epimastigote treated with the arylideneketones (1, 2, and 3). The arylideneketones along with Nfx and Bnz were evaluated at 24 h post- incubation with the parasite at 5X, 10X and 20X IC50. Arylidenketones 1 and 2 causes after 24 h late apoptosis/necrosis at a concentration of 20 times the value of its IC50 (approximately 80% of late apoptosis/necrosis) as Nfx. This necrotic effect of Nfx was also observed in our previous study by TUNNEL and 1H NMR. It should be studied what happens with compound 3 since no death is observed by apoptosis or necrosis at a dose of 20 times the value of their IC50 as Bnz. Probably, an autophagy process could be ongoing. Currently, we are performing studies in this sense. Acknowledgments: This work was supported by CSIC, PEDECIBA and Elena Aguilera is recipient of a ANII doctoral fellowship. |
Copyright
MDPI AG, the publisher of the Sciforum.net platform, is an open access publisher. We believe that authors should retain the copyright to their research works. Hence, by submitting a contribution to this conference, the authors retain the copyright of their contribution, but they grant MDPI AG the non-exclusive right to publish this contribution online on the Sciforum.net platform. This means the authors can easily submit their contribution to any scientific journal at a later stage and transfer the copyright to its publisher (if required by that publisher).
Best Presentation Award
This year, as a sponsor, Pharmaceuticals would like to award the best presentation as elected by all the organizers. The Award will consist of 500 Swiss Francs. We look forward to posting your contributions.
Criteria for Evaluation of Best Presentation Award 2017:
Criteria
- Full PPT presentation must be submitted to ECMC-3.
- The quality of the presentation.
- The scientific content of the presentation
Evaluation
- Each Evaluation Committee member will give an assessment for each applicant in terms of the criteria outlined above.
- Total score for each presentation will be ranked, from highest to lowest.
- If two or more students get the same score, further evaluation will be carried out.
- All decisions made by the Evaluation Committee are final.
Best Presentation at ECMC-3
Pharmaceuticals and the Organizing Committee of ECMC-3 congratulate Jalal Soubhye who received an award for the best presentation at ECMC-3:
Topic: Dual Anti-Inflammatory and Anti-Bacterial Effects of Phenylhydrazide and Phenylhydrazone Derivatives
authored by Jalal Soubhye,
Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles, Campusplaine, CP 205/5, 1050 Brussels, Belgium.
"Currently, Dr. Jalal Soubhye works as academic researcher at the Université Libre de Bruxelles (ULB) in the field of medicinal chemistry, whose research focuses on pharmacological design, synthesis and evaluation of new chemical substances with therapeutic potential. His current research interests are in the development and evaluation (in vitro and in vivo) of myeloperoxidase inhibitors as anti-inflammatory agents. Understanding of the mechanism of inhibition is very important to obtain new potent and safe inhibitors. In addition, he is working on design, synthesis and evaluation of new antimicrobial agents."
Exhibition Hall
Electronic Exhibition Hall of ECMC - Develop and Strengthen Your Brand
- Free of charge for companies exhibited in 2017.
- High visibility: The last edition of this series provided the opportunity to more than 10,000 visitors to browse
among 42 relevant slide shows and videos, presented by 150 authors from 22 countries. - Super easy to prepare: a short introduction of your company, and a PPT presentation (less than 10 slides) to show super star products.
Euriso-top Founded in January 1991 by a group of researchers from the Commissariat à l'Energie Atomique (CEA), Euriso-Top became a leading producer of deuterated solvents and stable isotope labelled compounds in Europe, thanks to an incomparable knowledge.
Read more...With a large catalog of thousands of chemical compounds covering various fields of application (Proteomics and Genomic research, Biotechnology discovery, Organic synthesis, Pharmaceutical development, Manufacturing industry), Euriso-top, has been supplying for 25 years the scientific community with stable isotope labeled chemicals, isotopic gases, NMR solvents, isotopic metals, Clinical trials substrates.
ELVESYS is an innovative self-funded company that started the commercialization of microfluidic instrumentation in 2011. ELVESYS aims to become a key research partner in the microfluidic field because we believe this domain will be the heart of next technological revolution.
Read more...Doubling its turnover every 9 months, in just 4 years its ELVEFLOW brand has become the world leader of high performance microfluidic flow control. Rewarded by more than 10 entrepreneurial distinctions, ELVESYS launched two sisters companies in 2013 and 2014, respectively specialized in the biological environment control, the microfluidic device design and fast microchip prototyping.
Hielscher Ultrasonics GmbH: High-power ultrasonic processors for liquid processing
Hielscher Ultrasonics specializes in the design, development and production of ultrasonic devices - both for use in laboratories as well as for industrial applications. Due to the outstanding power of the ultrasonic processors and the high quality standards, Hielscher became the world's leading supplier of high performance ultrasonic equipment. The product range of Hielscher Ultrasonics includes ultrasonic devices to / for
Read more...- Dispersing
- Synthesis of nanoparticles
- Desaggregieren / Disagglomerating
- Particle Size Reduction (Wet-milling / fine-grinding of micro-and nano-scale particles)
- Homogenization
- Emulsification
- Extraction
- acceleration of chemical reactions (Sonochemistry)
- Wire cleaning
A leading Belgian company distributing laboratory instruments and furniture.
As a distributor of laboratory instruments and lab furniture, Analis is primarily oriented towards research activities, biotechnology applications, chemistry, clinical chemistry and medical in vitro diagnostics and quality control.
Read more...We are actively involved in the biotechnological and pharmaceutical sector (from basic research to production), as well as in the agro and food industry. Our mission is to provide researchers in proteomics, genetics and cellular analysis with appropriate professional instruments and support tools.
Established in Namur in 1927, Analis employs more than 130 people in two locations: The head office is in Suarlée (NAMUR) in the south of Belgium and we have a branch office in Sint-Denijs-Westrem (GENT) in the north.
Thanks to acquisitions, distribution activities and constant innovation, our company has grown and integrated new technologies. Analis covers all aspects of laboratory management: from laboratory project design to complete maintenance of customer’s installed equipment. We structured our organization in order to guide each (research) laboratory with the necessary expertise, application support, technologies and solutions in the following fields: Life Sciences;- In Vitro Diagnostics; Laboratory Equipment; Analytical Chemistry; Materials Testing; Metrology; Laboratory Furniture by ARDESTA.
Our priority is to offer a high level of application and service support. Furthermore, by offering a full range of flexible automation systems, we help each laboratory to increase its lab productivity.
Analis is certified ISO9001-2008, including conception, production, distribution and technical assistance.
Analis also runs a research laboratory, ‘Analis R&D Diag’, that develops electrophoresis and CE in vitro diagnostic kits (CEOfix™). ANALIS R&D Diag is focused on analytical method development through the use of capillary
MDPI (Multidisciplinary Digital Publishing Institute) is an academic open-access publisher with headquarters in Basel, Switzerland. Additional offices are located in Beijing and Wuhan (China), Barcelona (Spain) as well as in Belgrade (Serbia).
Read more...MDPI publishes 179 diverse peer-reviewed, scientific, open access, electronic journals, including Molecules (launched in 1996; Impact Factor 2.861), the International Journal of Molecular Sciences (launched in 2000; Impact Factor 3.226), Sensors (launched in 2001; Impact Factor 2.677), Marine Drugs (launched in 2003; Impact Factor 3.503), Energies (launched in 2008; Impact Factor 2.262), the International Journal of Environmental Research and Public Health (launched in 2004; Impact Factor 2.101), Viruses (launched in 2009; Impact Factor 3.465), Remote Sensing (launched in 2009; Impact Factor 3.244), Toxins (launched in 2009; Impact Factor 3.030), Nutrients (launched in 2009; Impact Factor 3.550), and Pharmaceuticals (CiteScore 4.9). Our publishing activities are supported by more than 15,700 active scientists and academic editors on our journals' international editorial boards, including several Nobelists. More than 263,500 individual authors have already published with MDPI. MDPI.com receives more than 8.4 million monthly webpage views.
Tropical Medicine and Infectious Disease (ISSN 2414-6366) is an international, scientific, open access journal of tropical medicine and infectious disease published quarterly online by MDPI. It is the official journal of The Australasian College of Tropical Medicine.
All the latest news, products, jobs, events and much more pertaining to chemistry, life science and analytics can be found on the CHEMIE.DE online portals. bionity.com is our life science flagship. It addresses readers who are interested in facts and trends from life science, biotechnology and pharma—and all this in four different languages! A total of around 700,000 page views per month confirm there is great interest in bionity.com and its information services.
Pharmaceuticals (ISSN 1424-8247; CODEN: PHARH2) is an open access journal of medicinal chemistry and related drug sciences, published quarterly online by MDPI. Citations are available in PubMed, full-text archived in PubMed Central. Following Scopus, the 3-year *CiteScore* of Pharmaceuticals is 4.9 in 2016. Pharmaceuticals is now ranked #8/168 in the category "Pharmaceuticals Science".
LATOXAN is the leading producer of venoms from snakes, scorpions and batrachians with over 300 different venoms worldwide available. LATOXAN also produces and supplies venom toxins, plant, plant small molecules and screening libraries. LATOXAN supplies Pharmaceutical Industry, Academic and Pharma Research centres and worldwide distributors of Life Science Reagents.
Conference Organizers
Dr. Franck Vazquez, MDPI AG, Basel, Switzerland
Ms Changzhen Fu, MDPI AG Branch Office, Wuhan, China
Ms Flora Li, MDPI AG Branch Office, Wuhan, China
List of Keynotes & Videos
Old pharmaceuticals with new applications: the case studies of lucanthone and mitoxantrone
Related papers Old Pharmaceuticals with New Applications: the Case Studies of Lucanthone and Mitoxantrone
Synthesis,Characterization,Molecular docking and Structure-Activity Relationships of Novel Thiazolo[3,2-α]pyrimidines as Prospective Acetylcholinesterase Inhibitors
Related papers Synthesis, Characterization, Molecular docking and Structure-Activity Relationships of Novel 2-Arylidene- and 2-Aminomethylenethiazolo[3,2-a]pyrimidines as Prospective Acetylcholinesterase Inhibitors
Electrochemical Detection of Salmonella via On-surface Isothermal Amplification of its Genetic Materia onto Highly Stable and Reproducible Indium Tin Oxide Platforms
Searching for bioactive molecules in prostate cancer from Mayan traditional medicinal plants
C. Round Table on Nanomedicines
This round table is organized with the help of our media partner Precision Nanosystems.
Precision NanoSystems (PNI) creates innovative solutions for the discovery, development and manufacture of novel nanoparticles for use as medicines and in medical research. PNI headquarters is located in Vancouver, Canada with scientist and sales support located globally and our instruments in over 20 countries.
PNI’s proprietary NanoAssembler Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. This is illustrated by the one-hour video presenting breakthroughs in nanomedicines: https://youtu.be/hz27xoFddno.
Show all published submissions (1) Hide published submissions (1)
Submissions
List of Papers (1) Toggle list
D. Round Table on Parasitic Diseases
This round table is chaired by Dr. Conor Caffrey from the University of California at San Diego (USA).
Parasitic diseases continue to pose major public health problems, particularly in developing countries, worldwide. Moreover, the (re)appearance of these diseases in developed territories, such as schistosomiasis in Europe and Chagas disease in the southern United States, means that we must be increasingly vigilant in our preventive and response strategies as the global economy and climate change. However, the alarming ability of parasites to develop drug resistance combined with the small number of sometimes partially effective drugs available undermines our ability to manage and treat some diseases; a case in point being the emergence and establishment of drug resistance by the malaria parasite to artemisinin-based combination therapies (ACTs) over the last decade. Thus, there is a continuing, indeed, increasing, need to explore and develop new opportunities for chemotherapies. In this arena, the contribution of academia is vital. The current selection of papers submitted to this Round Table on Parasitic Diseases regarding leishmaniasis, trichomoniasis, Chagas disease, tuberculosis and Human African Trypanosomiasis attest to the continuing hard work and ingenuity of academic scientists to develop new ideas and approaches in the chemical battle against parasites. Importantly, in addition to synthetic chemical approaches described, we see the tapping of the vast chemical space of natural products as source of new drugs. It is hoped that the science presented at this Round Table will promote new exchanges and ideas among the chemical biology, parasitology and drug discovery communities, and ultimately contribute to the identification of novel therapeutic strategies.
Session Chair
Dr. Conor Caffrey
Show all published submissions (8) Hide published submissions (8)
Submissions
List of Papers (8) Toggle list